These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1783973)

  • 1. [Influence of the speed of spheronization on the physical properties and dissolution availability of theophylline minigranules prepared by extrusion-spheronization].
    Rahman L; Gaudy D; Bataille B; Jacob M; Puech A
    J Pharm Belg; 1991; 46(6):389-95. PubMed ID: 1783973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Parameters for the formulation of physical-technical characteristics of granules of theophylline obtained by extrusion-spheronization].
    Bataille B; Rahman L; Jacob M
    Pharm Acta Helv; 1991; 66(8):233-6. PubMed ID: 1758901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process.
    Karim S; Baie SH; Hay YK; Bukhari NI
    Pak J Pharm Sci; 2014 May; 27(3):425-38. PubMed ID: 24811797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of the extrusion die on pellet characteristics.
    Rabisková M; Weingartová D; Häring A
    Ceska Slov Farm; 2007 Jan; 56(1):17-20. PubMed ID: 17432277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the drying technique on theophylline pellets prepared by extrusion-spheronization.
    Pérez J; Rabisková M
    Int J Pharm; 2002 Aug; 242(1-2):349-51. PubMed ID: 12176277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process.
    Young CR; Koleng JJ; McGinity JW
    J Microencapsul; 2003; 20(5):613-25. PubMed ID: 12909545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption.
    Iosio T; Voinovich D; Grassi M; Pinto JF; Perissutti B; Zacchigna M; Quintavalle U; Serdoz F
    Eur J Pharm Biopharm; 2008 Jun; 69(2):686-97. PubMed ID: 18191390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of spherical pellets by a hot-melt extrusion and spheronization process.
    Young CR; Koleng JJ; McGinity JW
    Int J Pharm; 2002 Aug; 242(1-2):87-92. PubMed ID: 12176229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the formulation and process of Da Chuan Xiong Fang pellet by extrusion-spheronization].
    Hong YL; Feng Y; Xu DS; Jiang LH; Yang Y
    Zhong Yao Cai; 2007 Dec; 30(12):1596-600. PubMed ID: 18422197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of plate design on the properties of pellets produced by extrusion and spheronization.
    Michie H; Podczeck F; Newton JM
    Int J Pharm; 2012 Sep; 434(1-2):175-82. PubMed ID: 22659150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid.
    Krueger C; Thommes M
    Pharm Dev Technol; 2013 Feb; 18(1):225-35. PubMed ID: 22780876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug solubility effects on predicting optimum conditions for extrusion and spheronization of pellets.
    Hileman GA; Upadrashta SM; Neau SH
    Pharm Dev Technol; 1997 Feb; 2(1):43-52. PubMed ID: 9552430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suitability of a flat die press for the manufacture of pharmaceutical pellets by extrusion/spheronization.
    Ghanam D; Kleinebudde P
    Drug Dev Ind Pharm; 2011 Apr; 37(4):456-64. PubMed ID: 21446830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigations on the influence of the type of extruder for pelletization by extrusion-spheronization. II. Sphere characteristics.
    Thoma K; Ziegler I
    Drug Dev Ind Pharm; 1998 May; 24(5):413-22. PubMed ID: 9876603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of drug solubility on release behavior of calcium polysaccharide gel-coated pellets.
    Sriamornsak P; Kennedy RA
    Eur J Pharm Sci; 2007 Nov; 32(3):231-9. PubMed ID: 17889515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of 400 microm pellets by extrusion-spheronization: application with Gelucire 50/02 to produce a "sprinkle" form.
    Flament MP; Dupont G; Leterme P; Farah N; Gayot A
    Drug Dev Ind Pharm; 2004 Jan; 30(1):43-51. PubMed ID: 15000429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alginate-based pellets prepared by extrusion/spheronization: a preliminary study on the effect of additive in granulating liquid.
    Sriamornsak P; Nunthanid J; Luangtana-anan M; Puttipipatkhachorn S
    Eur J Pharm Biopharm; 2007 Aug; 67(1):227-35. PubMed ID: 17276664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gellan gum and polyvinylpyrrolidone (PVP) as binding agents in extrusion/spheronization pellet formulations.
    Barbosa EJ; Ferraz HG
    Acta Pharm; 2019 Mar; 69(1):99-109. PubMed ID: 31259713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral controlled release optimization of pellets prepared by extrusion-spheronization processing.
    Bianchini R; Vecchio C
    Farmaco; 1989 Jun; 44(6):645-54. PubMed ID: 2803450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.